AstraZeneca Pharma India (BOM:506820) EBIT : ₹2,207 Mil (TTM As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is AstraZeneca Pharma India EBIT?

AstraZeneca Pharma India's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ₹543 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹2,207 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. AstraZeneca Pharma India's annualized ROC % for the quarter that ended in Mar. 2024 was 37.75%. AstraZeneca Pharma India's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 183.42%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. AstraZeneca Pharma India's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 1.46%.

AstraZeneca Pharma India EBIT Historical Data

The historical data trend for AstraZeneca Pharma India's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Pharma India EBIT Chart

AstraZeneca Pharma India Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

EBIT

Get a 7-Day Free Trial

1,151.10

1,281.80

839.90

1,347.38

2,207.39

AstraZeneca Pharma India Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															233.68	715.51	738.65	210.12	542.91

Competitive Comparison of AstraZeneca Pharma India's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, AstraZeneca Pharma India's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AstraZeneca Pharma India's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca Pharma India's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where AstraZeneca Pharma India's EV-to-EBIT falls into.

AstraZeneca Pharma India EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹2,207 Mil.

AstraZeneca Pharma India (BOM:506820) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

AstraZeneca Pharma India's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	1825.04 * ( 1 - 27.37% )	/	( (0	+	3511.421)	/ 1 )
=	1325.526552	/	3511.421
=	37.75 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	0	-	0	-	( 0	-	max(0, 0	-	0	+	0	))
=	0

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	10780.283	-	2031.667	-	( 5237.195	-	max(0, 3571.177	-	9327.064	+	5237.195	))
=	3511.421

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

AstraZeneca Pharma India's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	2171.636	/	( ( (0 + max(0, 0))	+	(648.42 + max(535.579, 0)) )	/	1 )
=	2171.636	/	( ( 0	+	1183.999 )	/	1 )
=	2171.636	/	1183.999
=	183.42 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0)	-	(0	+	0	+	0)
=	0

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(1531.26	+	2278.82	+	278.53)	-	(2031.667	+	0	+	1521.364)
=	535.579

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

AstraZeneca Pharma India's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	2207.187	/	151121.287
	=	1.46 %

AstraZeneca Pharma India EBIT Related Terms

Thank you for viewing the detailed overview of AstraZeneca Pharma India's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

AstraZeneca Pharma India (BOM:506820) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca Pharma India Ltd (BOM:506820) » Definitions » EBIT

Traded in Other Exchanges

ASTRAZEN:India

Address

Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045

Website

https://www.astrazeneca.com

AstraZeneca Pharma India Ltd is engaged in the manufacture, distribution, and marketing of pharmaceutical products. Its only operating segment being Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation and Autoimmunity, Neuroscience and Infection and Vaccines.

AstraZeneca Pharma India (BOM:506820) Headlines

No Headlines